HVA vs IA/DA or VA in the Treatment of ND HR-AML

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Epistemonikos ID: a2668b8d93de18cfc94232b603b425d5aea6f134
First added on: Mar 27, 2025